23
ALL23
Dermata TherapeuticsYear
23
ALL6
20255
20245
20232
20224
20211
2020DEALS // DEV.
23
ALL10
Deals13
DevelopmentsCountry
23
ALL23
U.S.A23
ALL6
H.C. Wainwright & Co2
H.C. Wainwright & Co.13
Inapplicable1
Maxim Group LLC1
Revance TherapeuticsTherapeutic Area
23
ALL23
DermatologyStudy Phase
23
ALL18
Phase III2
Phase II3
Phase IDeal Type
23
ALL1
Agreement13
Inapplicable5
Private Placement4
Public OfferingProduct Type
23
ALL1
Other Large Molecule22
Other Small MoleculeDosage Form
23
ALL1
Topical22
Topical PowderLead Product
23
ALL5
DMT3101
DaxibotulinumtoxinA-lanm1
Hydrogen Peroxide1
Onabotulinumtoxin A15
XyngariTarget
23
ALL1
ACh release22
IL-17A receptorLead Product(s) : DMT310
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $6.2 million
Deal Type : Public Offering
Dermata Therapeutics Exercises Warrants for $6.2M Priced At-the-Market
Details : The net proceeds will used to support the clinical development of Xyngari (DMT310), which is being evaluated for the treatment of Acne Vulgaris.
Product Name : Xyngari
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 27, 2025
Lead Product(s) : DMT310
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $6.2 million
Deal Type : Public Offering
Lead Product(s) : DMT310
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BREAKING: Dermata's XYNGARI Phase 3 Trial Topline Data Meets All Primary Endpoints
Details : DMT310 (xyngari) is a novel, once-weekly, topical product candidate derived from a freshwater sponge being developed for the treatment of multiple skin diseases like Acne Vulgaris.
Product Name : Xyngari
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2025
Lead Product(s) : DMT310
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DMT310
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermata Completes Last Patient Visit in XYNGARI™ Phase 3 Acne Trial
Details : DMT310 (xyngari) is a novel, once-weekly, topical product candidate derived from a freshwater sponge being developed for the treatment of multiple skin diseases like Acne Vulgaris.
Product Name : Xyngari
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2025
Lead Product(s) : DMT310
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DMT310,Hydrogen Peroxide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $2.5 million
Deal Type : Private Placement
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement
Details : The net proceeds will used to support the company's late-stage product Exyngari (DMT310). It is being evaluated for the treatment of Acne Vulgaris.
Product Name : Xyngari
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 23, 2025
Lead Product(s) : DMT310,Hydrogen Peroxide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $2.5 million
Deal Type : Private Placement
Lead Product(s) : DMT310,Hydrogen Peroxide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $2.5 million
Deal Type : Private Placement
Dermata Therapeutics Announces $2.55M Private Placement Priced At-The-Market
Details : The net proceeds will used to support the company's late-stage product Exyngari (DMT310). It is being evaluated for the treatment of Acne Vulgaris.
Product Name : Xyngari
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : DMT310,Hydrogen Peroxide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $2.5 million
Deal Type : Private Placement
Lead Product(s) : DMT310,DaxibotulinumtoxinA-lanm
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Revance Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Dermata, Revance Partner on Xyngari(TM) with Daxxify(R) Clinical Collaboration
Details : Under the agreement, Both companies will evaluate the Xyngari (DMT310) in combination with Daxxify (daxibotulinumtoxinA-lanm) for the topical treatment of primary axillary hyperhidrosis.
Product Name : Xyngari
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 21, 2025
Lead Product(s) : DMT310,DaxibotulinumtoxinA-lanm
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Revance Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Xyngari
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
Details : DMT310 (xyngari) is a novel, once-weekly, topical product candidate derived from a freshwater sponge being developed for the treatment of multiple skin diseases like Acne Vulgaris.
Product Name : DMT310
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2024
Lead Product(s) : Xyngari
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xyngari
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $3.5 million
Deal Type : Private Placement
Dermata Closes $3.5M Private Placement, Priced At-The-Market
Details : The net proceeds will be used to support the clinical development of the company's lead product, DMT310, which is in late-stage trials for the treatment of acne vulgaris.
Product Name : DMT310
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : Xyngari
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $3.5 million
Deal Type : Private Placement
Lead Product(s) : Xyngari
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $3.5 million
Deal Type : Private Placement
Dermata Closes $3.5M Private Placement Priced At-The-Market
Details : The net proceeds will fund the clinical development of the company's lead product DMT310, which is being evaluated in the early-stage trial for Acne Vulgaris.
Product Name : DMT310
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 16, 2024
Lead Product(s) : Xyngari
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $3.5 million
Deal Type : Private Placement
Lead Product(s) : Xyngari
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : Undisclosed
Deal Type : Public Offering
Dermata Announces $2.66 Million Warrant Exercise Under Nasdaq Rules
Details : The net proceeds will be used in the clinical development of the lead product DMT310. Currently, it is being evaluated in late-stage clinical trial studies for the treatment of acne vulgaris.
Product Name : DMT310
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 17, 2024
Lead Product(s) : Xyngari
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : Undisclosed
Deal Type : Public Offering